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Background: Breast carcinoma can be classified as either Estrogen Receptor (ER) positive or negative by
immunohistochemical phenotyping, although ER expression may vary from 1 to 100% of malignant cells within an
ER + tumor. This is similar to genetic variability observed in other tumor types and is generally viewed as a
consequence of intratumoral evolution driven by random genetic mutations. Here we view cellular evolution within
tumors as a classical Darwinian system in which variations in molecular properties represent predictable adaptations
to spatially heterogeneous environmental selection forces. We hypothesize that ER expression is a successful
adaptive strategy only if estrogen is present in the microenvironment. Since the dominant source of estrogen is
blood flow, we hypothesized that, in general, intratumoral regions with higher blood flow would contain larger
numbers of ER + cells when compared to areas of low blood flow and in turn necrosis.
Methods: This study used digital pathology whole slide image acquisition and advanced image analysis algorithms.
We examined the spatial distribution of ER + and ER- cells, vascular density, vessel area, and tissue necrosis within
histological sections of 24 breast cancer specimens. These data were correlated with the patients ER status and
molecular pathology report findings.
Results: ANOVA analyses revealed a strong correlation between vascular area and ER expression and between high
fractional necrosis and absent ER expression (R2 = 39%; p < 0.003 and R2 = 46%; p < 0.001), respectively). ER
expression did not correlate with tumor grade or size.
Conclusion: We conclude that ER expression can be understood as a Darwinian process and linked to variations in
estrogen delivery by temporal and spatial heterogeneity in blood flow. This correlation suggests strategies to
promote intratumoral blood flow or a cyclic introduction of estrogen in the treatment schedule could be explored
as a counter-intuitive approach to increase the efficacy of anti-estrogen drugs.
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Estrogen (17β-estradiol) is a circulating steroid hormone
that binds to intracellular estrogen receptors (ER) after pas-
sively diffusing through the plasma membrane (Thomas
et al. [1]). Estrogen frequently plays a crucial role in breast
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ER expression in breast cancers is used as a prognostic and
predictive tool that reliably correlates with the clinical pro-
gression of disease and its response to hormonal therapies.
Although the ER status of breast carcinomas is typic-
ally expressed as simply positive or negative, there is
frequently considerable heterogeneity of ER expression
among cells of the same tumor. In fact, typical classifica-
tion of a tumor as ER positive requires only 1% of the cells
expresses ER (Hammond et al. [7]). There is now evidence
[8,9] that the prevalence of ER expression within cells in
the same tumor correlates with the degree and duration of
response to anti-estrogen therapy.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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logical forces that govern heterogeneity of ER expression
in breast cancers. Recent studies have demonstrated sub-
stantial heterogeneity in cells within the same tumor as a
result of intratumoral evolution [10-14]. Generally, this
heterogeneity is viewed as a genetic process in which
stochastic mutations generate new populations in an un-
predictable if not chaotic process. We note, however, that
genetic changes are simply one component of evolution
and that intratumoral Darwinian dynamics emerge funda-
mentally from environmental selection forces that promote
phenotypic (not genotypic) adaptations [15]. Furthermore,
we acknowledge that a large body of work exists which ad-
dresses the complex dynamics of ER expression in vitro
[16,17] and in vivo (Shipitson et al. [18]). We embrace these
works and do not suggest that phenotypic adaptation alone
is sufficient explain variation in ER expression.
Instead, we propose that intratumoral cellular heterogen-
eity represents a predictable process driven by variations in
environmental selection forces leading to predictable and
reproducible adaptive strategies. The most obvious source
of environmental selection is blood flow which, in most
cancers, is spatially and temporally heterogeneous resulting
in regions of necrosis in poorly perfused regions.
We propose that ER expression will be observed if it
provides an adaptive advantage. Specifically, we propose
that ER will be expressed only when estrogen is present
in the microenvironment. When estrogen is absent, ER
expression represents a needless expenditure of resources
and will be selected against. Since the source of estrogen
in the breast is typically (although not always) interstitial
fluid and moves from the vessels into the cell by a simple
reaction diffusion model identical to oxygen, nutrients,
etc. [19], we propose the hypothesis that ER + cells will
be found in regions of high blood flow while ER- cells will
be present in regions of poor blood flow. This results in
the prediction that the prevalence of ER + cells will gener-
ally follow the distribution of blood flow. To test this hy-
pothesis we examined regional distribution of ER + and
ER- cells compared to vascular density and regional ne-
crosis within 24 clinical breast cancers of variable ER sta-
tus and tumor grade.
Methods
Sample selection and collection
Twenty-four (24) clinically identified breast cancer cases
were selected via pathology report reviews by a board
certified pathologist (MMB) with the approval of the
University of South Florida Institutional Review Board
and the Moffitt Cancer Center Scientific Review Com-
mittee. Data for each case include the pathologist’s
estimation of percent ER + cells, ER stain intensity, and
the semi-quantitative Allred score [20] and histological
score. The cases cover a wide spectrum of diagnostic stagesincluding ductal carcinoma in situ (DCIS) (n = 11), invasive
ductal carcinoma Nottingham Grade I (n = 4), Grade II
(n = 4) and Grade III (n = 5). Similarly, the ER status, based
on the pathology report, ranged from 0- 100% positive and
the Allred and histological score were used to create four
classification ranges. The Allred score is the sum of a pro-
portion score reflecting the percentage of positive-staining
tumor cells (0, none; 1, 1⁄100; 2, 1⁄100 to 1⁄10; 3, 1⁄10 to 1⁄3;
4, 1⁄3 to 2⁄3; and 5, >2⁄3) and an intensity score representing
the average intensity of positive tumor cells (0, none; 1,
weak, 2, intermediate; and 3, strong). The proportion and
intensity scores are added to obtain a total score, which
ranges from 0 to 8. (Harvey [21]). The H score is a com-
bination of staining intensity and extent according to the
following formula: H score = 1 ×% of tumor cells with weak
staining + 2 ×% of tumor cells with moderate staining + 3
×% of tumor cells with strong staining, resulting in a total
score of 0 – 300 (Elston [22]). Although the ER intensity,
Allred and H-Scores were variable for the ER + cases used
to measure the vascular density and necrotic area, the per-
centage of ER positive cells in the positive cases was always
greater than 90%. This fact made it challenging to assess
the spatial distribution of ER positivity in these cases. An
additional five cases were selected with <60% ER positivity
and used to specifically evaluate the spatial distribution of
ER positivity with respect to vasculature.
The hematoxylin and eosin (H&E) stained sections used
for diagnosis from each identified case were retrieved from
the department archives and confirmed by the study path-
ologist (MMB). The blocks identified to have sufficient
material and most representative of each case was retrieved
from the Cancer Center archives for the purposes of these
studies.
Histology
For each of the 24 blocks selected for this study, serial
unstained sections were cut at a thickness of 4 μm using
standard microtomy practices and placed on charged
glass slides. The order in which the sections were cut
was recorded. The first section was stained with H&E,
using standard histological technique. The subsequent
serial sections were stained using a mouse monoclonal
antibody that reacts to CD34, (#CMA334, Cell Marque,
Rocklin, CA) at the stock prediluted concentration and
mouse monoclonal ER-β (#ab5786, Abcam, Cambridge,
MA) at 1:250 dilution and monoclonal antibody VEGF
VG1 (#M7273, Dako, Carpinteria, CA) at 1:500 dilution.
These slides were incubated for 16 minutes at room
temperature The Ventana OmniMap anti-mouse sec-
ondary antibody was incubated for 12 min. The Ventana
ChromoMap kit detection system was used according to
the kit protocol and slides were then counterstained with
hematoxylin. Appropriate positive and negative controls
were used. Slides were covered with #1.5 thick cover glass.
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Whole slide images (WSI) were produced using an Aperio
(Vista, CA, USA) ScanScope XT digital slide scanner with
a 20×/0.75NA lens. Using the Basler tri-linear array detec-
tion, stitching was minimized and the time to scan for
most WSIs did not exceed five minutes. Digital WSIs
were retained on servers housed within the Moffitt
Network Operations Center and accessible on any net-




The commercially available Genie histology pattern recog-
nition platform (Aperio) was trained to classify regions of
interest within each of the 13 invasive H&E stained sam-
ples. DCIS was analyzed separately to account for the cen-
tral comedo necrosis common to this non-invasive stage.
By manually selecting regions of necrosis, viable tumor
and other tissues (including, but not limited to: skin, adi-
pose tissue, and normal margins) the software was trained
with the following settings (1000 iterations of uniform dis-
tribution with 0.01 as a regularization parameter over 20
stage iterations with eight and three iterations per first
and second stage, respectively). Application of this train-
ing set over the entire WSI for each patient allowed for
computationally derived region segmentation. Each case
was carefully quality controlled by a board certified path-
ologist (MMB).
Vasculature identification and quantification
The CD34 stained slides were segmented by the region
classification methods described above. Furthermore, the
CD34 positive vessels were identified using the Aperio
vasculature algorithm with the following settings
(Lumen and closed vessels including incomplete vessels
with filtering = 2; low = 160; high =210; with stain com-
ponents .27, .57 and .78 [RGB]). This algorithm was used
to export the quantified values for vessel perimeter, area
and lumen area.
ER identification and quantification
The ER stained slides were segmented by region classifi-
cation methods using Definiens Tissue Studio (Munich,
Germany). The DCIS and invasive tumor components
were identified as the regions of interest and each cell
was segmented and classified into negative (masked blue),
low (yellow), moderate (orange) and high (red) intensity
using the following parameters (IHC Thres = 0.5; Thres
low/moderate = 0.75; Thres moderate/high = 1.0)
Resultant classification images from the cell identifica-
tion, segmentation and classification methods were over-
lain with vessel mask images from CD34 staining using
Image Pro Plus v.6.0.1 (Media Cybernetics, Bethesda,MD). These images were used to measure the shortest dis-
tance between each cell and the nearest identified vessel.
Statistical analysis
A partially-hierarchical ANOVA (SYSTAT version 13) ana-
lysis was used to test for the effects vessel number, four
parameters of vessel size (mean vessel area, mean vessel
perimeter, maximum vessel size and mean lumen area)
and the percentage of tissue which is necrotic on the
tumor grade and ER status of each case. The dependent
variables were the different feature data (i.e. vessel number,
mean lumen area and percentage of necrotic area) and the
independent variables were ER status and tumor grade.
The 24 cases being analyzed were the samples.
Results
Vasculature availability
CD34 positive blood vessels within a manually edited
buffer of 300 μm from any tumor cell in all directions
were identified and individually quantified for each sam-
ple. The metrics collected included the number of vessels
in the sample. No correlation between vessel number and
ER status was elucidated (R2 = 7%; p = 0.689).
The vessel size (mean vessel area, mean vessel perim-
eter, maximum vessel area and mean lumen area)) of the
blood vessels was much lower in the samples which did
not express ER compared to the ER + samples as evi-
denced in Figure 1 and Table 1. In aggregate the ER- sam-
ples exhibited a mean vessel area of 176 μm2 compared to
359 μm2 in ER + patients (R2 = 37%; p = 0.003). The per-
imeter increased from 87 μm in ER- to 151 μm in ER +
(R2 = 40%; p = 0.003). Even the maximum vessel area and
lumens of the vessels increased from 25 μm2 in ER- to
41 μm2 in the ER + cohort (R2 = 18%; p = 0.059). To re-
iterate, the mean vessel diameter of the vasculature of
the ER + regions was about twice that of the vessels if
ER- samples in each of the three measures. Vessels iden-
tified in the ER- regions never exceeded a mean area
over 300 μm2 while 14 of the 18 ER + cases exhibited a
mean exceeding 300 μm2 with a maximum of 671.4 μm2
(Table 2) (R2 = 16%; p = 0.08). Vessel size was not found
to be correlated with disease progression (p = 0.295). In
other words, vessel size was not statistically different in
DCIS samples compared to those of grade I, II or III in-
vasive cancers yet the same metrics of vessel size was
highly correlated with ER status (Figure 2). Further-
more, the vascular density (vessels/area) was not corre-
lated with ER status or disease progression (p = 0.476).
Increasing mean vessel area is associated with in-
creasing tumor perfusion which might represent poten-
tial good prognostic value [23], and increasing survival
rate [24], because tumor oxygenation increases survival
rate through improving radiation, chemotherapy and
reduces metastatic potentiality (Overgaard et al. [25-27];













Figure 1 Vascular quantification. This graph demonstrates the quantified vascular differences between ER + and ER- samples. Largely, the ER +
samples exhibit vessel area, perimeter length and lumen size which are statistically significant to demonstrate increased size as compared to the
vessels in ER- samples.
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mors have relatively higher average vessel size that might
indicate good prognostic value in compare to ER-negative
tumors (Teschendorff et al. [29]; [30]).
The spatial distribution of ER positivity with respect to
vasculature has been of great interest. Five IDC cases were
stained with ER (<60% positivity) were used to specifically
evaluate the spatial distribution of ER positivity with respect
to identifiable blood vessels. Here the study pathologist
(MMB) identified visible vasculature directly from the ER
stained slides and from CD34 stained serial sections. Larger
vessels were clearly identifiable and demonstrated prox-
imal (<30 μm) ER positivity in 76.5% (26 of 34) visible ves-
sels. Furthermore, for all lesions proximal to vasculature
the overall ER positivity was 43.3% and the moderate to
strong positivity was 31.5% whereas, conversely, in the le-
sions distant to vessels ER positivity dropped to 26.3% and
the moderate to strong positivity was observed to be 9.3%.
Necrosis
Necrosis was once often associated with poor vascu-
larization, subsequent hypoxia and the resultant cell deathTable 1 Vascular quantification
ER- Er+
Mean vessel area (um2) 175.6 358.5
Mean vessel perimeter (um) 87.1 151.2
Mean lumen area (um2) 24.6 40.7
Quantified values of mean vascularity for ER + and ER- patients.[31,32]. Other studies have shown that in fact high
vascularization is correlated with necrotic zone expansion
[33]. In this study necrosis was segmented from the viable
tumor and other tissues including normal margins, adipose
tissues et cetera. First, it was necessary to segment the pa-
tients by diagnosis so central comedo necrosis commonly
found in DCIS patients did not over inflate the re-
sults of the invasive population. Regardless of the
diagnosis, the viable tumor to necrotic area ratio was
calculated for each sample (Table 2). Summary statis-
tics were calculated by ER negative and ER positive
groups for each diagnostic category. The mean necro-
sis area in invasive ER- samples was observed to be
24.3%. By contrast, necrosis was quantified to be 4.2%
in ER + tumor samples, demonstrating significantly
lower necrosis in ER + tumors as compared to ER- tu-
mors (R2 = 46%; p < 0.001). Of the ER + invasive sam-
ples 8 of 11 had less than 5% necrosis (Figure 3).
Similarly, the DCIS ER- group exhibited 21.3% necro-
sis area per total tumor area while ER + DCIS cases were
quantified to contain 4.4% necrosis. Of the DCIS ER +
samples 6 of 8 had less than 5% necrosis. These data
demonstrate in this sample group that ER-negative tumors
have higher necrotic core area relative to viable tumor
area. Furthermore, the amount of necrosis in DCIS sam-
ples was not found to be dependent on the size of the
DCIS or the availability of vasculature outside of the base-
ment membrane of the duct itself. Initially, we hypothe-
sized in DCIS increased necrosis would correlate with
ductal size and in turn the distance from the center of the

































Patient 1 - 0 0 0 0 2.12E-04 1301 197.3 91.5 47.5 23.1
Patient 2 - 0 0 0 0 7.97E-05 153 63.1 41.4 7.7 69.3
Patient 3 - 0 0 0 0 3.67-04 2124 224.4 107.4 21.2 <.5
Patient 4 - 0 0 0 0 5.19E-05 329 102.8 58.2 8.2 16.2
Patient 5 - 0 0 0 0 1.14E-03 12195 287.9 141.5 34.4 22.4
Patient 6 - 0 0 0 0 1.56E-03 8609 178.0 82.9 28.9 14.9
Patient 7 + 90 1+ to 3+ 6 150 6.19E-04 13082 482.8 195.7 72.3 33.7
Patient 8 + 95 1+ to 3+ 7 155 4.35E-04 4560 307.4 142.1 44.6 1.1
Patient 9 + 95 1+ to 3+ 7 165 8.38E-04 12672 282.1 122.8 40.4 <.5
Patient 10 + 90 2+ 7+ 170 7.23E-04 14879 347.7 153.3 34.8 22.1
Patient 11 + 100 1+ to 3+ 8 200 4.79E-05 1784 368.6 138.2 33.3 4.7
Patient 12 + 95 1+ to 3+ 7 240 5.39E-04 6274 267.6 107.4 61.5 <.5
Patient 13 + 100 2 + 0 to 3+ 8 260 5.59E-05 7927 671.4 258.4 16.5 5.2
Patient 14 + 90 3+ 8 270 9.18E-04 19704 465.8 191.7 23.2 2.5
Patient 15 + 90 3+ 8 270 7.66E-04 16094 341.9 130.9 21.7 <.5
Patient 16 + 100 2+ to 3+ 8 270 4.67E-04 1712 178.8 98.7 40.4 1.6
Patient 17 + 100 2+ to 3+ 8 270 7.27E-04 19485 436.3 174.1 29.3 <.5
Patient 18 + 100 2+ to 3+ 8 280 8.26E-04 4379 221.2 110.9 65.8 <.5
Patient 19 + 100 3+ 8 300 2.35E-04 1619 172.4 80.6 30.9 3.9
Patient 20 + 100 3+ 8 300 8.78E-05 3673 312.2 152.3 17.6 <.5
Patient 21 + 100 3+ 8 300 5.03E-04 8258 271.8 115.4 47.7 <.5
Patient 22 + 100 3+ 8 300 4.87E-04 17390 373.7 158.7 52.3 <.5
Patient 23 + 100 3+ 8 300 7.74E-04 14857 512.3 237.2 58.8 <.5
Patient 24 + 100 3+ 8 300 7.03E-04 11188 438.0 156.7 40.9 <.5
Neg control NA NA NA NA NA 1.72E-04 2207 116.1 59.3 6.3 NA
Pos control NA NA NA NA NA 9.78E-04 11836 345.8 156.3 22.4 NA
Summary of all quantification metrics for all patients.
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results. The average diameter of ER- DCIS with central
necrosis was 668 μm. The average diameter of ER +DCIS
without central necrosis was 702 μm. Examples of the
levels of necrosis in ER = and ER- samples are available in
Figure 4. Also of interest, in a single case vasculature was
observed inside the DCIS. This case was not found to
contain necrosis and was ER + (Figure 4E). Finally, adja-
cent normal breast tissues were also investigated to
understand whether or not the vasculature of adjacent
normal tissues correlated with the ER positivity in the
nearest lesions. The vascularization studies were per-
formed on ten samples which we either 0% ER + (n = 5)
or >90% ER + (n = 5). However, there were no observ-
able differences between the vessel features in the adja-
cent normal tissues.Discussion
ER expression is a useful predictive and prognostic bio-
marker in breast cancer, however, is often extremely
variable even within the same tumor. Similar to cellular
heterogeneity found in other cancers [10-14], this vari-
ation in ER staining is a consequence of intratumoral
evolutionary dynamics (Figure 5). Here we address the
Darwinian dynamics that might govern cellular ER ex-
pression. There are two general components of ER evo-
lution. The first, which cannot be answered with our
current study, is the variability of ER expression in the
same tumor. Can breast cancer cells adjust ER expres-
sion (and other growth factor receptors) so that ER +
and - cells in the same tumor represent a single generalist
population that phenotypically adapts to various envi-






Figure 2 Representative vasculature images. A) ER- Grade III invasive breast cancer tumor stains against CD34 with as few as 13 quantified
vessels at a region adjacent to the tumor edge. Scale = 800 μm. This may be compared with B) ER + CD34 stained grade III tumor which has as
many as 84 vessels in the same area as evidenced by C) and D) which are enlarged views of the inset areas with quantified vessels of each
masked in red. Scale bar = 200 μm.
Figure 3 Invasive necrosis quantification. Viable tumor is selected via histological pattern recognition software (Genie; Aperio) in green. Other
tissues are classified in red and necrotic tissues are classified as blue. In the top panel A) and B) and ER + sample is presented in comparison to
C) and D) in which an ER- sample is shown. Area of necrosis as a percentage of total tumor area (viable tumor and necrotic region) data for each
sample is presented. Scale bar = 5 mm.





Figure 4 Ductal carcinoma in situ localization. This is a DCIS lesion from A) an ER- patient with central necrosis. Note the regionally adjacent
vessels outside the lesion (blue arrows) and B) the enlarged image of the central necrosis localized under the black arrow. C) DCIS from an
ER + patient without central necrosis despite the size and distance from the center to vasculature; D) as illustrated by the lack of necrosis in the
enlarged region uder the black arrow. E) Shows a large (>1 mm) DCIS sample with interior vasculature. This sample does not exhibit necrosis and
this patient is ER+. Top row scale bars = 250 μm; bottom row scale bars = 100 μm.
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represent separate, specialist populations. The second
component of intratumoral Darwinian dynamics is the
environmental factors that are selection forces that
define phenotypic fitness. This is the focus of our
current work.
Here we propose that spatial heterogeneity in ER expres-
sion is the sequela of intratumoral evolution driven not by
random mutations but by variations in environmentalFigure 5 ER positivity in DCIS relative to vascular localization: A) DCIS
stroma and the individual cells were segmented and classified as neg
stain intensity expression. Simultaneously CD34 serial sections were used
demonstrates an overlain image set of ER classification and vessel localizati
expression than cells distant from the vessels. Scale bars = 250 μm.selection forces and predictable cellular adaptive strategies.
We specifically hypothesize that ER expression will correl-
ate with local concentrations of estrogen. Since estrogen
diffusion from blood vessels is spatially limited by reac-
tion–diffusion kinetics similar to oxygen and glucose, we
predict a correlation between vascularization, necrosis
and ER expression (Teschendorff et al. [29]; [30-32]). In
order to test cell density as a plausible barrier of diffu-
sion we evaluated the mean cell number per mm2 andlesions stained this ER were B) isolated from the adjacent
ative (blue), weak (yellow), moderate (orange) and strong (red)
to identify, isolate and mask (red) vessels. Together this image
on. Cells nearer the vasculature were observed to have stronger ER
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evaluated. This suggests cell density alone does not cor-
relate with ER status.
Our results do show that ER + tumors are associated
with larger blood vessels and a lower percentage of tis-
sue necrosis. It should however be noted that differences
in CD34 staining may over or underestimate the vascular-
ity due to tumor-specific alterations in the vascular bed
such that not all of the endothethial cells may be appreci-
ated. Our initial prediction that vessel number will in-
crease in ER + samples was not supported. However, the
interaction between vessel size and ER status was three
times higher than the interactions between tumor grade
and ER status and vessel area. Our second hypothesis, that
ER status would be inversely correlated with necrosis, was
even more strongly supported. This suggests that as ductal
carcinoma in situ progresses towards invasion, 1) the
larger the vasculature is early in disease progression, the
lower the volume of necrosis and 2) if necrosis does not
increase with the cancer progression, then ER + cells are
more likely to dominate the population.
While the number of patients evaluated in this study
is limited, and a larger patient population would be
desirable, the number of individual vessels evaluated is
on the order of 103 to 104 per patient. For this reason,
our results indicate statistical significance to detect dif-
ferences between ER positive and negative patients.
Furthermore, the amount of necrosis in DCIS samples
was not found to be dependent on the size of the DCIS
or the availability of vasculature outside of the basement
membrane of the duct itself. Initially, we hypothesized in
DCIS increased necrosis would correlate with ductal size
and in turn the distance from the center of the gland to
vascular resources. This was not the case in our results.
Also of interest, in a single case vasculature was observed
inside the DCIS. This case was not found to contain ne-
crosis and was ER + (Figure 4E).
Poor vascularization and necrosis was originally hy-
pothesized to be a proxy for hypoxia induced cell death
and thus an indicator of low estrogen availability. How-
ever, there are a number of plausible explanations (many
of which may be responsible in part) why necrotic re-
gions may play a role. In our previous work, we hypoth-
esized that tumor heterogeneity could be predictable
similar to that of a riparian zone in a desert environ-
ment. Oxygenated phenotypes or relatively highly per-
fused regions could be equivalent to mesic species and
poorly vascularized (distal from a blood supply) would
be equivalent to xeric species [15]. In this regard, ER-
positive phenotypes are mesic while ER-negatives are
xeric phenotypes.
Xeric habitats are formed by evaporation of water and
accumulation of salt which results in salty soil that select
for xeric species. In our scenario, hypoxic phenotypesmay be shaped by a depletion of nutrients, oxygen and
metabolites. That is why ER-negative cells may be adapted
to tissue of poor vascularization and higher necrosis. Of
course toxification (i.e. salty soil) in such an environment
may be another plausible consideration. Regardless, this
unavailability of estrogen is one reasonable explanation
for estrogen-independent tissue selection. This may be a
testable hypothesis in vitro or using techniques including
laser capture microdissection to isolate specific regions of
high vascularity within patient tumors and evaluating the
estrogen concentrations. This is a key future direction for
this research.
A significant limitation of our analysis is our inability
to measure temporal variations in blood flow. That is,
the cyclical and random variations in blood flow which
have been extensively observed. These variations will
result in temporal variations in estrogen concentration
which could alter ER expression. This imprecise link of
vascular density and blood flow could result in similar
variations in the correlation between vascular density
and ER expression.
Conclusion
In conclusion, we find ER expression and metrics of vas-
cular density and blood flow in 24 clinical breast cancers
show direct correlations between ER + tumors and blood
vessel size and inverse correlation with necrosis consist-
ent with predictions. This correlation, if confirmed, sug-
gest strategies to promote intratumoral blood flow could
be explored as a somewhat counter-intuitive approach
to increase the efficacy of anti-estrogen drugs.
Due to natural selection, ER- tumors could be evolving
in a way that resists (adapts to) the absence of estrogen.
As a future direction, we hypothesize that anti-estrogen
therapy (e.g. Tamoxifen) can select for ER-independent
cells. In contrast, cyclic introduction of estrogen may im-
prove survival rate by continually altering, rather than
unilaterally shifting, toward an ER- population. In other
words, this theory suggests that modulation (and not
eradication or extinction of certain population) may prove
to be an advantageous treatment strategy.
Furthermore, it may be possible that ER + cells cluster
around vasculature and effectively act as a barrier. While
this is a future direction of this research and has not yet
been tested, it may explain how both populations coexist
spatially in a single tumor. More interestingly, it may
also be possible that this spatial pattern keeps ER- cells
farther from blood vessels where they might enter the
bloodstream and form metastatic tumors. ER- may be
more prone to metastasize if ER + cells are less success-
ful invading novel tissues. Future work should determine
the spatial relationships around vasculature and the pro-
pensity for each population to metastasize. This more in
depth assessment of regional distributions of ER + and
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erogeneous ER staining correlates directly with vessel
distribution (i.e. whether ER + cells congregate nearer to
the vessels within a tumor).
In summary, we conclude that ER status is selected for
given vascular availability which could have meaningful
and exploitable therapeutic decision making implications.
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